• Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page

Sanofi pays $110M upfront for late-stage radioligand therapy, setting up rivalry with Novartis

cafead

Administrator
Staff member
  • cafead   Sep 12, 2024 at 11:42: AM
via Sanofi has made a late entry to the radioligand party, paying 100 million euros ($110 million) upfront for global rights to a neuroendocrine tumor treatment that is nearing a filing for approval.

article source